ANN ARBOR, Mich.--(EON: Enhanced Online News)--RetroSense Therapeutics (www.retro-sense.com) announced today that it has been identified and selected by Windhover (Elsevier Business Intelligence) as a “Top Project to Watch: Most Licensable Products.” RetroSense Therapeutics is a privately held biotechnology company at the forefront of developing optogenetic therapies for vision restoration.
“Top Project to Watch: Most Licensable Products.”
The Top Projects to Watch are “hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products." "Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said David Cassak, Vice President, Content, Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
“We are delighted to receive this accolade, which reflects the excitement surrounding our lead product RST-001, and the promise it holds in vision restoration,” said RetroSense Therapeutics CEO, Sean Ainsworth. “We are making significant and rapid advancements in the development of RST-001, which we look forward to discussing at the Therapeutic Area Partnerships Conference.”
Mr. Ainsworth will be presenting on behalf of RetroSense Therapeutics in the “Advanced Therapeutics” category at the Therapeutic Area Partnerships Conference on November 19, 2013.
About RetroSense Therapeutics
RetroSense Therapeutics is a biotechnology company developing game-changing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. RetroSense Therapeutics is led by a team of seasoned veterans with experience in developing some of the most successful drugs on the market and numerous successful new business ventures.
About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.
RetroSense Forward-Looking Statement
This press release includes forward-looking statements regarding the therapeutic and commercial potential of RetroSense’s technologies and products in development. Any statement describing RetroSense’s goals, intentions, beliefs, expectations, financial or other projections is a forward-looking statement and should be considered an at-risk statement. RetroSense’s forward-looking statements also involve assumptions that, if incorrect, could cause the Company’s results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements reflect the good faith judgment of RetroSense management, however, these statements are based solely upon elements currently known by RetroSense. Readers are cautioned not to rely on these forward-looking statements.